Arizona Urology Specialists

Tucson, Arizona 85745

1 studies enrolling now · 14 studies all time

What they study most

Androgen Resistant Prostatic Cancer, Benign Prostatic Hyperplasia (BPH), Bladder Cancer, Bladder Pain Syndrome, Cancer of the Prostate, Hormone Sensitive Prostate Cancer, Interstitial Cystitis, Metastatic Castrate-sensitive Prostate Cancer, Metastatic Castration Resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Non-muscle Invasive Bladder Cancer

Studies at this site

• Post-Market Study to Assess iTind Safety in Comparison to UroLift — Recruiting now
• A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer — Recruiting now
• Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy — Recruiting now
• A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer — Recruiting now
• Safety, Efficacy, and Frequency of Administration of VNX001 in the Treatment of Interstitial Cystitis / Bladder Pain Syndrome (IC/BPS) — Recruiting now
• A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC — Running, not enrolling
• Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) — Running, not enrolling
• A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer — Running, not enrolling
• RESTORE: An RCT to Evaluate the Efficacy of the Revi System — Running, not enrolling
• A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer — Running, not enrolling
• Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC — Running, not enrolling
• A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases — Completed
• A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer — Running, not enrolling
• Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent — Stopped early